Celiac Disease Treatment Market Size & Share 2026-2035

Celiac Disease Treatment Market Size

The global celiac disease treatment market was estimated at USD 712.6 million in 2025. The market is expected to grow from USD 782 million in 2026 to USD 2 billion in 2035, growing at a CAGR of 10.8% during the forecast period, according to the latest report published by Global Market Insights Inc.

The heighted incidence of celiac disease as well as the growing awareness among healthcare providers regarding the availability of advanced diagnostic products are the major factors that raise the number of people diagnosed with celiac disease, contributing to the demand for effective treatment that boosts market growth. For example, as per the Celiac Disease Foundation report, about 1 in 100 people globally are affected by celiac disease. Moreover, the development of innovative diagnostic products and the introduction of non-invasive testing such as serological tests improves the diagnostic process helps in early diagnosis of celiac disease, thereby raises the demand for treatment options, that contribute to market growth. Therefore, the rising awareness pertaining to disease among people and healthcare professionals, and advancement in diagnostic techniques has increased the number of target population required therapeutic and supportive interventions boosts market growth.

Additionally, the increasing research and development activities for the development of pharmaceutical treatments options such as larazotide acetate which is further expected to launch in the market soon, propelling growth of celiac disease treatment options during the forecast period. Moreover, the increasing usage of gluten-free diets, among non-celiac population, with the rising growth of non-invasive diagnostic tools, such as advanced serological tests, has enhanced the accuracy of tests with reduced diagnostic time contribute market growth. For example, technologies such as HLA typing and improved antibody testing have increased the testing rates by 8.5% annually. Thus, with the rise in technological advancement in diagnostics, the number of people diagnosed with the disease increases and has resulted in an increase in demand for effective therapeutics options, subsequently boosting market growth.

The celiac disease treatment market includes the healthcare industry, focused on managing and treating celiac disease. It is a chronic autoimmune disorder activated by the ingestion of gluten in genetically predisposed individuals. The market for celiac disease treatment encompasses a wide variety of pharmaceutical products, supplements and therapies to reduce the symptoms, prevent complications, and improve the quality of life for affected individuals. Key players such as Takeda Pharmaceutical Company, Novartis, Amgen, Teva Pharmaceutical, and BioLineRx dominate the global celiac disease treatment market. These players are contributing to market growth through introduction of novel products, continuous investment in research and development, expansion of clinical pipelines, and strategic collaborations aimed at developing innovative therapeutic approaches for improved disease management.

Between 2022 to 2024, the global celiac disease treatment market witnessed significant growth from USD 533.4 million in 2022 to USD 649.9 million in 2024. Expansion of specialized gastroenterology clinics and improved access to autoimmune disease management services increased treatment adoption among diagnosed patients. Growing investment by pharmaceutical companies in clinical trials for targeted immunotherapies and enzyme-based treatments also supported market expansion. In addition, rising availability of nutritional supplements and supportive therapies for long-term disease management improved patient adherence to treatment plans. Increasing healthcare expenditure and stronger distribution networks for prescription medications and medical nutrition products further contributed to the steady growth of the celiac disease treatment industry during this period.

Celiac Disease Treatment Market Trends

The global celiac disease treatment industry is experiencing significant growth owing to several key trends that are creating new opportunities and market expansion.

• The continuous innovation in medicinal therapies such as the development of novel drug delivery systems and medicinal therapies, that includes enzymatic treatments, immune-modulators, and vaccine research is creating new treatment possibilities that foster market growth.

• The potential for new treatment strategies is latiglutenase enzyme therapy, which may reduce gluten toxicity. In addition, there is significant investment in R&D on targeted treatment options for celiac disease by pharmaceutical companies. For example, Takeda Pharmaceuticals and Innovate Biopharmaceuticals are concentrating on immune-modulating therapies and biologics that are expected to accelerate market growth.
• Moreover, the rise in healthcare spending in developed and developing economies enables better access to therapy and diagnosis. Thus, the rise in healthcare spending with insurance coverage for the diagnosis and treatment of celiac disease has increased the adoption of treatment options, thereby driving market growth.
• Additionally, the increasing fast-track approvals of promising drugs for celiac disease treatment by regulatory authorities such as U.S. FDA and European Medicine Agency (EMA), introducing potential drugs in the market, that contribute to market growth. For example, the FDA has granted Innovate Biopharmaceuticals larazotide fast track designation for celiac disease. Thus, the increase in the number of products approved by the regulatory bodies in U.S. and Europe drives the growth of the market.
• Furthermore, the increase in the number of ongoing clinical trials for celiac disease owing to rising government funding has increased the research and development activities for the development of novel treatment, spur the market growth. For instance, the National Institute of Health (NIH) funded several ongoing studies that are focused on celiac disease treatment and research, this will lead to introduction of new drug in the market, thereby contributing to market growth.

Celiac Disease Treatment Market Analysis

Based on treatment, the market is bifurcated into vitamins and minerals supplements, gluten-free diet and medical therapies. The vitamins and minerals supplements segment dominated the market and was valued at USD 345.4 million in 2025 and is anticipated to reach USD 950.7 million by 2035.

• Celiac disease reduces the absorption of iron, calcium, vitamin D, B12, and folate owing to damaged small intestine by the disease. For example, as per an article published, it has been reported that the levels of vitamin D in pediatric celiac disease (CD) patients were usually lower than in healthy person. Therefore, vitamins and supplements are required to nurture an improved diet, thereby contributing to market growth.
• Additionally, vitamins and minerals are important in the treatment of celiac disease as it can help repair the gut lining. Thus, the patients suffering from celiac disease increases the intake of calcium and vitamin D as these nutrients contribute to moderate bone health which is often a problem in celiac patients because of malabsorption.
• Moreover, the market growth is fueled by increasing customer demand for specialized vitamins and minerals products for patients suffering from celiac disease. Such products raise consumers’ interest as they support gut health, thereby fostering market growth.
• On the other hand, the medical therapies segment is poised to witness growth at 11.1% CAGR during the analysis period due to increasing development of targeted pharmaceutical treatments aimed at managing the immune response triggered by gluten exposure.
• In addition, growing clinical trials, rising interest in disease-modifying therapies, and increasing demand for alternatives beyond strict gluten-free diets are encouraging the adoption of medical therapies, thereby driving segment growth.

Based on the route of administration, the global celiac disease treatment market is categorized into oral and parenteral. The oral segment accounted for the highest market share of 63.3% in 2025 and is anticipated to witness growth at a CAGR of 10.7% during the analysis period.

• Oral treatments offer better ease, as patients can easily take them home without any assistance from healthcare providers or specialized equipment.
• Moreover, the U.S. FDA and other regulatory agencies provide fast-track designation to various oral dosage form for the treatment of celiac disease, thus the rising demand for new therapies, and the ongoing research and development activities leads to introduction of effective oral dosage form with better efficacy thereby contributing to market growth. For example, in November 2024, Immunic, Inc. developed a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6 (Sirtuin 6) has entered phase 1/1b clinical trials.
• Additionally, the advancement of novel oral formulations like enzyme supplements and immune modulators have increased the number of treatment options available for patients. Thus, the purpose of these new formulations is to enhance efficacy, bioavailability, and easy absorption of drugs, that contribute to market growth.
• Furthermore, medication taken orally is usually more convenient than injections and infusions. Most patients prefer oral therapies as they are easy to take, which is favorable for people with tight schedules to take medicine on time, without any requirement of hospital visit. Thus, the advantages offered by oral treatment help the market to grow.
• On the other hand, the parenteral segment is expected to grow at 11% CAGR over the coming years.
• The growth can be attributed to the increasing development of biologic and injectable therapies designed to modulate immune responses associated with celiac disease.
• Additionally, factors such as improved drug bioavailability, rapid therapeutic action, and better efficacy for advanced or refractory cases further support the growth of this segment.

Based on the end use, the global celiac disease treatment market is categorized into hospitals, specialty clinics, homecare settings, and other end users. The hospitals segment dominated the market in 2025 and is anticipated to reach USD 1 billion by 2035, growing with a CAGR of 10.7% during the analysis period.

• Anti-inflammatory drugs and therapeutic vaccines are setting a new direction in treatment, which makes hospitals try to broaden their services and allows usage of these drugs for the treatment. In addition, the advancement in diagnostic tools, and the availability of different treatment options in hospital settings have improved the patient’s outcomes leading to market growth. For example, in September 2024, AliveDx receives IVDR-CE mark for multiplexed assay to accurately detect celiac disease (CD) on the MosaiQ system.
• Additionally, hospitals offer the patients first line treatments for celiac disease like nutrition therapy, gluten free diet, and biologicals which are not available at primary care centers.
• Moreover, the hospital offers multidisciplinary care to the patients with the easy availability of specialized gastroenterologists, dieticians, immunologists, and endocrinologists. The availability of specialized panels of doctors and surgeons ensure comprehensive treatment for celiac disease, thereby contributing to market growth.
• In addition, hospitals are more often the primary site for clinical trials, the key pharmaceutical players collaborated with hospitals for the testing of new drug molecule, offering advanced treatment options for the patients, that spur market growth.
• Furthermore, patients’ dependence on biological agents and enzyme increases the number of visits to hospitals. These procedures and therapies often lead to inpatient admissions for further observation which in turn accelerates the market growth.

North America Celiac Disease Treatment Market

The North America celiac disease treatment industry held the largest share of 44.2% in 2025 and is anticipated to expand at 10.6% CAGR over the forecast period.   

• The growth is due to the strong presence of advanced healthcare infrastructure and well-established pharmaceutical companies actively involved in autoimmune disease research.
• The region benefits from high adoption of specialty treatments, strong reimbursement frameworks, and increasing clinical research activities focused on novel therapies for celiac disease, thereby contributing to market growth.

In 2025, the U.S. held a significant position in the North America celiac disease treatment industry and was valued at USD 284.6 million.

• The number of cases of celiac disease continues to increase in U.S., led to increasing demand for better treatment options. For instance, as per the report the U.S. represented over 88.4 % of the total North American celiac disease, indicating a very high patient base.
• Moreover, the U.S. FDA has applied firm regulation on the labelling of gluten-free products, these regulations will help patients suffering from celiac disease to manage their conditions more effectively by easily identifying gluten-free products, this will rise the demand for treatment options, thereby spur market growth.
• Additionally, the continual medical research into novel treatment approaches and modernized diagnostic systems and therapies is likely to propel market growth. Major companies search for new avenues to differentiate themselves in the market to grow, which foster growth. For instance, Zedira’s Larazotide acetate and Immunic’s IMU-838 are trying to mitigate the unwanted immune system reactions in celiac patients, which is one of the most important unmet medical needs.
• Besides, both government and private organizations trying to enhance research and development activities offer funding, which helps to develop new therapies to augment the current treatment protocols. For instance, the National Institute of Health, NIH, funded USD 10 million dollars in May 2024 to help understand celiac disease better and assist in developing newer treatments.

Europe Celiac Disease Treatment Market

Europe celiac disease treatment industry was valued at USD 179.8 million in 2025 and expected to reach USD 501.7 million by 2035.

• The growth of this region is driven by the increasing prevalence of autoimmune gastrointestinal disorders and the growing availability of specialized treatment options across the region.
• In addition, improved patient support programs, wider availability of prescription medications and nutritional therapies, and the growing role of patient advocacy organizations promoting disease management are contributing to the expansion of the market in Europe.

Germany shows strong growth potential in the Europe celiac disease treatment market in 2025.

• The increasing prevalence of celiac disease in Germany with supportive regulatory bodies that are actively promoting the control and treatment of disease boosts market growth.
• Moreover, the easy availability of gluten-free products in the country coupled with the increasing demand for dietary minerals and supplements for the management of disease, contribute to market growth. For example, in 2023 the German Center for Health Research (DZG) announced partnership with major food products manufacturers to ensure the availability of certified gluten-free labeling on products in German supermarkets. In addition, the gluten-free products industry in Germany is growing rapidly owing to increasing adoption of product due to medical conditions and lifestyle change, this will make gluten-free more affordable in the country thereby propelling the market growth.
• Furthermore, the increasing research and development activities to introduce novel drugs therapies to offer better safety and efficacy in the treatment has contributed to the demand for celiac disease treatments in Germany. For example, in 2022 the German Federal Ministry of Education and Research (BMBF), allocated funds to research organization and academic institutes to develop advanced treatment options for celiac disease, this will drive the growth of market during the analysis period.
• Additionally, the German government and health authorities have been active to educate public through health campaigns about gluten intolerance and celiac disease drives the market growth.

Asia Pacific Celiac Disease Treatment Market

Asia Pacific market is expected to experience growth at 11.2% CAGR over the forecast period.

• The growth is driven by the rising awareness of celiac disease, increasing adoption of diagnostic and therapeutic interventions, and improving healthcare infrastructure across the region.
• Additionally, increasing disposable incomes, greater access to prescription medications, and government initiatives promoting autoimmune disease management are supporting the adoption of celiac disease treatments in Asia Pacific.

China to experience the highest growth rate in the Asia Pacific celiac disease treatment market in 2025.

• The change in dietary habits and increasing adoption of western-style food in the county leads to a rise in celiac disease, that contributes to market growth.
• In addition, the Chinese government has also been actively trying to better the public’s gastrointestinal health, which includes celiac disease. Besides, greater funding aimed for the improvement of the public’s health also increases the demand for different treatment options, such as gluten-free diet, and thus promotes market growth.
• Additionally, the increasing awareness of celiac disease by medical professionals in China, leads to increasing number of people diagnosed with this disease, this rise in prevalence of disease raises the demand for advanced treatment options, thereby contributing the market growth. For example, as per the study published in American Journal of Gastroenterology, it has been reported that 1 in 100 individuals in China may have celiac disease.
• Furthermore, China’s growing international trade and tourism have also contributed to an increase in the impending spread of disease, this necessitating better treatments and awareness contribute market growth.

Latin America Celiac Disease Treatment Market

Brazil's celiac disease treatment industry is projected to witness highest growth in Latin America during the upcoming years.

• Strict regulatory laws by Brazilian government to specify gluten content and increasing consumer preference and awareness for gluten-free and celiac-safe lifestyle, leads to increase in adoption of such products, thereby contributing to market growth. For example, ANVISA (Agencia Nacional de Vigilancia Sanitaria) the regulatory authority in Brazil enforced strict regulations for the labelling of gluten content on the food products, this will help in provide safer access of gluten-free product to celiac disease patient, thereby contributing the market growth. 
• Furthermore, the availability of proven therapies, for the treatment of celiac disease has positively influenced the market. Additionally, the increasing partnership with global pharmaceutical companies provide access for novel treatment options that has driven its adoption in Brazil.

Middle East & Africa Celiac Disease Treatment Market

Saudi Arabia is anticipated to grow in the Middle East and African celiac disease treatment industry in 2025.

• The expansion of specialized clinics and hospitals facilities in Saudi Arabia that offers specialized services for gastrointestinal disease including celiac drives the market growth.
• Moreover, Saudi Arabia is collaborating with universities and international research bodies to develop and import innovative celiac disease treatments formulation, thereby fostering market growth.
• Furthermore, Saudi Arabia have a high expatriate population that have high risk of celiac prevalence, propelling the demand for gluten-free products thereby contributing to the market growth.

Celiac Disease Treatment Market Share

Top 5 players including Amneal, Glenmark, Takeda, Teva Pharmaceuticals and Novartis accounted for approximately 48.2% share of the market in 2025. These players have demonstrated a strong focus on strategies such as acquisition, business expansion, research and development activities and novel product launches to consolidate their market presence. For instance, in October 2022, Takeda and Dr. Falk Pharma GmbH announced a collaboration and licensing agreement to develop ZED1227/TAK-227, a Phase 2b investigational therapy for the treatment of celiac disease. TAK-227, a potential first-in-class therapy that aims to mitigate the unwanted immune response to gluten in celiac disease, is part of a increasingly growing competitive market.

The market for the treatment of celiac disease is exceptionally competitive, dominated by well-known and new pharmaceutical companies, which competition is mostly focused on price, new product development, and advanced treatment formulation. Strategic competitive advantage is gained through joint ventures, merger and acquisition activities which facilitates product diversification and enhanced market access. In addition, efforts to increase the regions’ sustainable practices, affordability, and accessibility will assist in gaining traction and allowing market players to strengthen their positions globally.

Celiac Disease Treatment Market Companies

Prominent players operating in the global celiac disease treatment industry are as follows:

• ActoBio
• Amgen
• Amneal Pharmaceuticals
• BioLineRx
• Calypso Biotech
• General Mills
• Glenmark Life Sciences
• Hikma Pharmaceuticals
• Innovate Biopharmaceutical
• Novartis
• Takeda Pharmaceutical Company
• Teva Pharmaceutical
• Viatris
• Zydus Pharmaceuticals 

Takeda Pharmaceutical Company

Takeda is a leading player in the celiac disease treatment market with approximately 15.9% of market share, leveraging its strong pipeline of investigational therapies and expertise in autoimmune gastrointestinal disorders. The company’s global presence, strategic collaborations, and robust clinical development programs enhance treatment accessibility and adoption, driving market growth and strengthening its leadership position.

Novartis

Novartis contributes to market expansion through its innovative therapeutic platforms and focus on immune-mediated disorders. The company’s strategic partnerships, advanced R&D capabilities, and established global distribution networks support timely development and commercialization of celiac disease treatments, ensuring broad patient reach and adoption.

Amgen

Amgen strengthens the celiac disease treatment market with its biologics expertise and targeted immunotherapy programs. Its well-established global operations, strong pipeline of immune-modulating therapies, and focus on research in autoimmune disorders drive adoption, improve patient outcomes, and reinforce its competitive position.

Celiac Disease Treatment Industry News

• In December 2025, RheumaGen, a cell and gene therapy company developing novel autoimmune disease treatments, received a Series A-1 investment from Beyond Celiac Investments (BCI) to advance its celiac disease program and demonstrate preclinical proof of concept. The funding provided RheumaGen with the resources to accelerate early-stage development, strengthened its research capabilities, and increased its potential to attract future investors and strategic partnerships in the celiac disease market.
• In May 2025, Teva Pharmaceutical Industries announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for its investigational anti-IL-15 antibody, TEV-53408, aimed at treating adults with celiac disease adhering to a gluten-free diet. TEV-53408 is currently undergoing a Phase 2a clinical trial to evaluate its safety and efficacy in this patient population. This designation enabled Teva to accelerate the development and review process, potentially bringing the therapy to market faster and strengthening its position in the celiac disease treatment market.
• In September 2024, Barinthus Biotherapeutics announced the initiation of its first-in-human Phase 1 trial of VTP-1000 in adults with celiac disease. The randomized, placebo-controlled clinical trial, which includes a controlled gluten challenge, will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VTP-1000. This product launch in the upcoming year will boost market growth significantly.
• In December 2022, Nemysis Ltd and Faran S.A. sign a strategic agreement to cooperate for the development of endopeptidase E40 for celiac disease. This will help to broaden the treatment availability.
• In October 2022, Takeda and Dr. Falk Pharma GmbH announced a collaboration and licensing agreement to develop ZED1227/TAK-227, a Phase 2b investigational therapy for the treatment of celiac disease. This product approval in the future marked a significant advancement in the availability of effective treatments for celiac disease.

The celiac disease treatment market research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment

• Vitamins and minerals supplements
• Gluten-free diet
• Medical therapies

Market, By Route of Administration

• Oral
• Parenteral

Market, By End Use

• Hospitals
• Specialty clinics
• Homecare settings
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina

• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE